M&A

Infrareal Holding has announced that it has entered into a corresponding transfer agreement with Takeda to acquire the 24-hectare site in Orth, Lower Austria – subject to merger control approval from Austrian regulators.

According to the company’s press release, this acquisition will help Infrareal realise its goal of becoming a leading operator of pharma and biotech locations in German-speaking countries across Europe. Through its subsidiary, PharmaparkOrth Management, Infrareal will be responsible for all site maintenance including engineering services, waste and recycling, and other infrastructure. As part of this, 34 Takeda employees related to engineering and infrastructure will transition over to PharmaparkOrth Management.

CEO and spokesperson for the management of Infrareal, Dr Martin Egger, stated, “Over the last 40 years and more, Orth an der Donau has developed into a centre of excellence for the pharmaceutical and life science industries, focusing on gene and cell therapy and biologics. Our expertise will help us to further expand the site, and we are hoping to attract more companies from these industries.”

Matt Payne, head of Global Biologics Operating Unit at Takeda, added, “With Infrareal, we have found an experienced pharmaceutical and life science site operator who plans to further develop the Orth site and who can build on the existing knowledge. We are pleased to have found a buyer who shares our ambitions for sustainable processes and site decarbonisation.”